168 related articles for article (PubMed ID: 37012938)
41. Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment.
Grünwald V; Merseburger AS
Onco Targets Ther; 2012; 5():111-7. PubMed ID: 22787405
[TBL] [Abstract][Full Text] [Related]
42. Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors.
Eskens FA; de Jonge MJ; Bhargava P; Isoe T; Cotreau MM; Esteves B; Hayashi K; Burger H; Thomeer M; van Doorn L; Verweij J
Clin Cancer Res; 2011 Nov; 17(22):7156-63. PubMed ID: 21976547
[TBL] [Abstract][Full Text] [Related]
43. Tivozanib for the treatment of metastatic renal cancer.
Wong HH; Eisen T
Expert Rev Anticancer Ther; 2013 Jun; 13(6):649-60. PubMed ID: 23773100
[TBL] [Abstract][Full Text] [Related]
44. A phase II study of tivozanib in patients with metastatic and nonresectable soft-tissue sarcomas.
Agulnik M; Costa RLB; Milhem M; Rademaker AW; Prunder BC; Daniels D; Rhodes BT; Humphreys C; Abbinanti S; Nye L; Cehic R; Polish A; Vintilescu C; McFarland T; Skubitz K; Robinson S; Okuno S; Van Tine BA
Ann Oncol; 2017 Jan; 28(1):121-127. PubMed ID: 27771610
[TBL] [Abstract][Full Text] [Related]
45. Efficacy, Safety, and Tolerability of Tivozanib in Heavily Pretreated Patients With Advanced Clear Cell Renal Cell Carcinoma.
Johns AC; Campbell MT; Gao M; Hahn AW; Lim Z; Wang E; Gao J; Shah AY; Msaouel P; Tannir NM
Oncologist; 2024 Mar; ():. PubMed ID: 38478923
[TBL] [Abstract][Full Text] [Related]
46. Tivozanib: current status and future directions in the treatment of solid tumors.
Pal SK; Bergerot PG; Figlin RA
Expert Opin Investig Drugs; 2012 Dec; 21(12):1851-9. PubMed ID: 23013465
[TBL] [Abstract][Full Text] [Related]
47. The progression free survival-plateau with vascular endothelial growth factor receptor inhibitors--is there more to come?
Grünwald V; Merseburger AS
Eur J Cancer; 2013 Jul; 49(11):2504-11. PubMed ID: 23601669
[TBL] [Abstract][Full Text] [Related]
48. First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials.
Takyar S; Diaz J; Sehgal M; Sapunar F; Pandha H
Anticancer Drugs; 2016 Jun; 27(5):383-97. PubMed ID: 26886011
[TBL] [Abstract][Full Text] [Related]
49. Axitinib in Metastatic Renal Cell Carcinoma.
Mittal K; Wood LS; Rini BI
Biol Ther; 2012; 2(1):5. PubMed ID: 24392298
[TBL] [Abstract][Full Text] [Related]
50. Tivozanib: First Global Approval.
Kim ES
Drugs; 2017 Nov; 77(17):1917-1923. PubMed ID: 28971328
[TBL] [Abstract][Full Text] [Related]
51. Cabozantinib in the treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor targeted therapy: clinical trial evidence and experience.
Osanto S; van der Hulle T
Ther Adv Urol; 2018 Mar; 10(3):109-123. PubMed ID: 29662541
[TBL] [Abstract][Full Text] [Related]
52. Efficacy of everolimus in patients with advanced renal cell carcinoma refractory or intolerant to VEGFR-TKIs and safety compared with prior VEGFR-TKI treatment.
Kato R; Obara W; Matsuura T; Kato Y; Iwasaki K; Fujioka T
Jpn J Clin Oncol; 2014 May; 44(5):479-85. PubMed ID: 24688083
[TBL] [Abstract][Full Text] [Related]
53. A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma.
Bitting RL; Healy P; Creel PA; Turnbull J; Morris K; Wood SY; Hurwitz HI; Starr MD; Nixon AB; Armstrong AJ; George DJ
Clin Genitourin Cancer; 2014 Aug; 12(4):241-50. PubMed ID: 24685058
[TBL] [Abstract][Full Text] [Related]
54. Tivozanib for the treatment of renal cell carcinoma: patient selection and perspectives.
Rodenburg RJ; Eskens F
Int J Nephrol Renovasc Dis; 2019; 12():137-141. PubMed ID: 31190952
[TBL] [Abstract][Full Text] [Related]
55. What is next in second- and later-line treatment of metastatic renal cell carcinoma? review of the recent literature.
Mori K; Schmidinger M; Quhal F; Egawa S; Shariat SF; Grünwald V
Curr Opin Urol; 2021 May; 31(3):276-284. PubMed ID: 33742984
[TBL] [Abstract][Full Text] [Related]
56. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.
Cabebe E; Wakelee H
Curr Treat Options Oncol; 2007 Feb; 8(1):15-27. PubMed ID: 17634832
[TBL] [Abstract][Full Text] [Related]
57. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.
Shah AY; Kotecha RR; Lemke EA; Chandramohan A; Chaim JL; Msaouel P; Xiao L; Gao J; Campbell MT; Zurita AJ; Wang J; Corn PG; Jonasch E; Motzer RJ; Sharma P; Voss MH; Tannir NM
Eur J Cancer; 2019 Jun; 114():67-75. PubMed ID: 31075726
[TBL] [Abstract][Full Text] [Related]
58. A Profile of Avelumab Plus Axitinib in the Treatment of Renal Cell Carcinoma.
Tiako Meyo M; Chen J; Goldwasser F; Hirsch L; Huillard O
Ther Clin Risk Manag; 2022; 18():683-698. PubMed ID: 35837579
[TBL] [Abstract][Full Text] [Related]
59. The safety and efficacy of nivolumab for the treatment of advanced renal cell carcinoma.
Ornstein MC; Rini BI
Expert Rev Anticancer Ther; 2016 Jun; 16(6):577-84. PubMed ID: 27144724
[TBL] [Abstract][Full Text] [Related]
60. Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma.
Auvray M; Auclin E; Barthelemy P; Bono P; Kellokumpu-Lehtinen P; Gross-Goupil M; De Velasco G; Powles T; Mouillet G; Vano YA; Gravis G; Mourey L; Priou F; Rolland F; Escudier B; Albiges L
Eur J Cancer; 2019 Feb; 108():33-40. PubMed ID: 30616146
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]